AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination

By Reuters News

- AstraZeneca AZN.L and Daiichi Sankyo 4568.T have entered into a clinical collaboration with Summit Therapeutics SMMT.O to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple tumour types, including lung and breast cancers.

  • The companies said on Friday that they intend to begin with a Phase III trial in first-line triple-negative breast cancer

  • The deal builds on AstraZeneca's $2 billion investment in Summit to collaborate on a series of studies testing their cancer treatments together

  • Under the agreement, each company will contribute its respective medicine and share trial costs, while retaining development and commercial rights to their own drugs

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk